속새 (호스테일)

Possible Drug-Herb Interaction between Herbal Supplement Containing Horsetail ( Equisetum arvense) and Antiretroviral Drugs.

1. J Int Assoc Provid AIDS Care. 2017 Jan/Feb;16(1):11-13. doi: 10.1177/2325957416680295. Epub 2016 Nov 30. Possible Drug-Herb Interaction between Herbal Supplement Containing Horsetail ( Equisetum arvense) and Antiretroviral Drugs. Cordova E(1), Morganti L(1), Rodriguez C(1). Author informatio

Evaluation of the Clinical Efficacy of a Novel Palmitoylethanolamide-Equisetum arvense Supplement for the Management of Chronic Pain: Findings from a Prospective Clinical Trial.

1. Med Sci (Basel). 2025 Sep 3;13(3):169. doi: 10.3390/medsci13030169. Evaluation of the Clinical Efficacy of a Novel Palmitoylethanolamide-Equisetum arvense Supplement for the Management of Chronic Pain: Findings from a Prospective Clinical Trial. Invernizzi M(1)(2), Mulè S(3), Lippi L(2), Galla R(4), Folli A(1)(2), Ferrari S(3), Tiso D(5), Uberti F(3). Author information: (1)Department of Health Sciences, University of Piemonte Orientale (UPO), 28100 Novara, Italy. (2)Translational Medicine, Dipartimento Attività Integrate Ricerca e Innovazione (DAIRI), Azienda Ospedaliero-Universitaria (AOU) SS, Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy. (3)Department for Sustainable Development and Ecological Transition, University of Piemonte Orientale (UPO), 13100 Vercelli, Italy. (4)Noivita Srls, Spin Off, University of Piemonte Orientale (UPO), Strada Privata Curti 7, 28100 Novara, Italy. (5)Department of Clinical Nutrition, "Villa Maria" Hospital, 47921 Rimini, Italy. Background: Chronic pain represents a major therapeutic challenge due to the limited efficacy and tolerability of conventional pharmacological treatments. Equisetum arvense L., a medicinal plant with potent antioxidant properties, and palmitoylethanolamide (PEA), an endogenous fatty acid amide with well-established anti-inflammatory and analgesic effects, are increasingly recognised as promising nutraceutical agents. Methods: This prospective, single-centre clinical trial aimed to evaluate the efficacy and safety of a novel oral supplement (Assonal®PEA) combining 600 mg of PEA and 300 mg of Equisetum arvense L. in improving the reduction of pain and quality of life in patients with chronic pain, also obtaining information on the patient's state of satisfaction after the treatment. Fifty patients suffering from chronic pain (low back pain and radiculopathy) for two months were enrolled and received the supplement over eight weeks in a tapered regimen (two tablets daily for two weeks, followed by one tablet daily). Results: Clinical outcomes were evaluated using validated instruments, including the Numeric Pain Rating Scale (NPRS), Verbal Rating Scale (VRS), Short-Form McGill Pain Questionnaire (SF-MPQ), Global Perceived Effect (GPE), and EuroQol-5D-5L. Results showed a significant decrease in pain intensity (NPRS: -3.8 points; VRS: -2.1 points; p < 0.0001), along with meaningful improvements in patient-perceived benefit, pain descriptors, and quality of life (EQ-5D-5L: +35%; p < 0.0001). Conclusions: These findings endorse the use of this novel PEA-Equisetum arvense formulation as a safe, well-tolerated, and potentially effective supplementary intervention for managing chronic pain. No adverse events were reported, and the overall response rate reached 94%. DOI: 10.3390/medsci13030169 PMCID: PMC12452663 PMID: 40981167 [Indexed for MEDLINE] Conflict of interest statement: Rebecca Galla is an employee of Noivita Srls and did not play a role in interpreting the data. Domenico Tiso, medical manager of Agave Group srl, did not play a role in interpreting the data. Francesca Uberti is a co-founder of Noivita Srls. The remaining authors declare that the research was conducted without commercial or financial relationships that could be construed as a potential conflict of interest.

Relative absorption of silicon from different formulations of dietary supplements: a pilot randomized, double-blind, crossover post-prandial study.

2. Sci Rep. 2021 Aug 13;11(1):16479. doi: 10.1038/s41598-021-95220-2. Relative absorption of silicon from different formulations of dietary supplements: a pilot randomized, double-blind, crossover post-prandial study. Boqué N(#)(1), Valls RM(#)(1)(2), Pedret A(3)(4), Puiggrós F(1), Arola L(1)(5), Solà R(1)(2)(6). Author information: (1)Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició I Salut, Av. de La Universitat, 43204, Reus, Spain. (2)Functional Nutrition, Oxidation and Cardiovascular Diseases Group (NFOC-Salut), Facultat de Medicina I Ciències de La Salut, Universitat Rovira I Virgili, Reus, Spain. (3)Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició I Salut, Av. de La Universitat, 43204, Reus, Spain. anna.pedret@eurecat.org. (4)Functional Nutrition, Oxidation and Cardiovascular Diseases Group (NFOC-Salut), Facultat de Medicina I Ciències de La Salut, Universitat Rovira I Virgili, Reus, Spain. anna.pedret@eurecat.org. (5)Facultat de Química, Grup de Recerca en Nutrigenòmica, Universitat Rovira I Virgili, Tarragona, Spain. (6)Hospital Universitari Sant Joan de Reus, Reus, Spain. (#)Contributed equally The purpose of the present study was to compare the relative absorption of a new powder presentation of silicon (Si) as orthosilicic acid with maltodextrin (Orgono Powder) compared to usual Si liquid presentations as orthosilicic acid with Equisetum arvense and Rosmarinus officinalis (G5 Siliplant) and orthosilicic acid with aloe vera (G7 Aloe). All dietary supplements were administered at the same Si oral dose (21.6 mg) in a randomized, double-blind, crossover post-prandial study conducted in 5 healthy men. Urine was collected at baseline and over the 6-h post-dose period in 2 separate 3-h collections for the analysis of Si concentration, which was conducted by inductively coupled plasma optical emission spectrometry as the gold standard method. No significant differences in total urinary Si excretion were found after the intake of these 3 dietary supplements; 34.6%, 32.4% and 27.2% of the ingested Si from G7 Aloe, G5 Siliplant and Orgono Powder, respectively, was excreted in urine over the 6-h follow-up period. The 3 different oral Si formulations tested, in powder and liquid presentations, provide highly bioavailable Si and present an equivalent relative absorption in healthy humans. © 2021. The Author(s). DOI: 10.1038/s41598-021-95220-2 PMCID: PMC8363645 PMID: 34389753 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no competing interests.

A randomized, open-label, multicenter, comparative study of therapeutic efficacy, safety and tolerability of BNO 1030 extract, containing marshmallow root, chamomile flowers, horsetail herb, walnut leaves, yarrow herb, oak bark, dandelion herb in the treatment of acute non-bacterial tonsillitis in children aged 6 to 18 years.

3. Am J Otolaryngol. 2019 Mar-Apr;40(2):265-273. doi: 10.1016/j.amjoto.2018.10.012. Epub 2018 Oct 24. A randomized, open-label, multicenter, comparative study of therapeutic efficacy, safety and tolerability of BNO 1030 extract, containing marshmallow root, chamomile flowers, horsetail herb, walnut leaves, yarrow herb, oak bark, dandelion herb in the treatment of acute non-bacterial tonsillitis in children aged 6 to 18 years. Popovych V(1), Koshel I(2), Malofiichuk A(2), Pyletska L(2), Semeniuk A(2), Filippova O(2), Orlovska R(2). Author information: (1)Ivano-Frankivsk National Medical University, Galitskaya str. 2, 76000 Ivano-Frankivsk, Ukraine. Electronic address: popovych_ent@ukr.net. (2)Ivano-Frankivsk National Medical University, Galitskaya str. 2, 76000 Ivano-Frankivsk, Ukraine. Seventy to 95% of acute tonsillitis episodes are caused by viral infection, therefore why antibiotic therapy is not indicated in majority of cases. In such cases, acetaminophen or ibuprofen are used to alleviate the symptoms. The objective of this study was assessment of efficacy of phytoneering extract BNO 1030 (Imupret®) in patients with acute non-bacterial tonsillitis. METHODS: This randomized, open-label, multicenter, comparative study randomised 238 outpatients aged 6-18 years to receive either BNO 1030 (Imupret®) as a supplement to standard symptomatic therapy, or standard therapy. Assessment criteria were as follows: sore throat dynamics at rest and at swallowing, throat irritation associated with cough, general condition, day of withdrawal of antipyretics, the share of treatment responders, as well as assessment of "therapeutic benefit" from the use of BNO 1030. RESULTS: Decreased intensity of acute tonsillitis symptoms to 1 point and lower, assessed using 4-point scale starting from the day 5 of treatment (p < 0.005), alleviation of local symptoms and general condition starting from day 2 of the disease (р < 0.001), withdrawal of antipyretics starting from day 4 of treatment (p < 0.005), increase of the number of treatment responders to 81.6% (p < 0.005) versus the control were reported. "Therapeutic benefit" was 4.2 days. All patients tolerated phytotherapy well, and no adverse reactions were seen. CONCLUSION: BNO 1030 (Imupret®) is a safe and effective product for treatment of acute non-bacterial tonsillitis in children aged 6-18 years, assuring therapeutic benefit when prescribed additionally to the standard symptomatic therapy. Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved. DOI: 10.1016/j.amjoto.2018.10.012 PMID: 30554882 [Indexed for MEDLINE]

Silicon Resorption from Equisetum arvense Tea - A Randomized, Three-Armed Pilot Study.

4. Planta Med. 2022 Nov;88(14):1360-1368. doi: 10.1055/a-1643-5493. Epub 2021 Oct 27. Silicon Resorption from Equisetum arvense Tea - A Randomized, Three-Armed Pilot Study. Waterstradt A(1), Winker M(#)(2), Zimmermann-Klemd AM(#)(1), Devi S(#)(1), Lederer AK(1), Huber R(1), Gründemann C(2). Author information: (1)Centre for Complementary Medicine, Department of Medicine II, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany. (2)Translational Complementary Medicine, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. (#)Contributed equally Equisetum arvense tea (TEA) contains high concentrations of silicon and has been used in folk medicine for the treatment of inflammatory ailments. We examined the resorption of silicon after TEA consumption. Safety and immunological effects were secondary outcomes. A monocentric, randomized, three-armed pilot study was conducted with 12 voluntary, healthy, male subjects. The study is registered in the German register for clinical trials (DRKS-ID: DRKS00016628). After a low silicon diet for 36 hours, 1000 mL TEA1 with approximately 200 000 µg silicon/L, TEA2 with approximately 750 000 µg silicon/L, or Si-low-Water (approximately 10 - 10 000 µg silicon/L as a control) were ingested on three consecutive days. Blood and urine samples were collected at baseline, day 1 examining silicon kinetics, day 3 examining silicon accumulation, and day 8 (safety, immunological parameters). Si-low-Water intake did not change silicon serum (Cmax 294 µg/L) or urine (19 000 µg/24 h) concentrations compared to baseline. Cmax was 2855 µg/L for TEA1 and 2498 µg/L for TEA2; tmax was 60 and 120 min, respectively. Silicon accumulation did not occur. Urine silica within 24 h (E24 h) was higher after TEA2 compared to TEA1 ingestion (142 000 vs. 109 000 µg/24 h). Serum silicon levels at t = 120 min differed significantly after intake of TEA2 or intake of Si-low-Water (p = 0.029). The immunological parameters did not show any significant changes indicating immunosuppressive effects in volunteers. TEA1 was well tolerated, while TEA2 caused diarrhoea in 4 subjects. Our investigations show that intake of TEA1 leads to significant rise in serum silicon concentration. Thieme. All rights reserved. DOI: 10.1055/a-1643-5493 PMID: 34706374 [Indexed for MEDLINE] Conflict of interest statement: The authors declare that they have no conflict of interest.

A randomised, double-blind, placebo-controlled clinical trial assessing the efficacy of bedtime buddy® for the treatment of nocturnal enuresis in children.

5. BMC Pediatr. 2019 Nov 9;19(1):421. doi: 10.1186/s12887-019-1797-8. A randomised, double-blind, placebo-controlled clinical trial assessing the efficacy of bedtime buddy® for the treatment of nocturnal enuresis in children. Schloss J(1)(2), Ryan K(1), Reid R(1)(2), Steel A(3)(4). Author information: (1)Office of Research, Endeavour College of Natural Health, Brisbane, Australia. (2)Australian Research Centre in Complementary and Integrative Medicine, Faculty of Health, University of Technology Sydney, Sydney, Australia. (3)Office of Research, Endeavour College of Natural Health, Brisbane, Australia. amie.steel@uts.edu.au. (4)Australian Research Centre in Complementary and Integrative Medicine, Faculty of Health, University of Technology Sydney, Sydney, Australia. amie.steel@uts.edu.au. BACKGROUND: Nocturnal enuresis (NE), or 'bedwetting', is a form of night-time urinary incontinence occurring in younger children. A diagnosis of NE can be socially disruptive and psychologically stressful for a child. The most common strategies used by parents to manage NE are waking the child during the night to use the bathroom and limiting the child's water intake before going to bed. Behavioural or educational therapies for NE such as urotherapy or bladder retraining are widely accepted and considered as a mainstream treatment option for non-neurogenic lower urinary tract dysfunction in children. Pharmacotherapy also plays an ancillary role. However, there is no gold standard therapy or intervention to effectively manage NE. METHODS: This study aims to determine the efficacy of a herbal combination in the treatment of NE in children. The target population for this study is 80 children aged between 6 and 14 years old (males and females) who have primary nocturnal enuresis ≥3 per week (wet nights). The active group will receive one or two capsules per day containing 420 mg of a proprietary blend of Urox® (Seipel Group, Brisbane, Australia) containing Cratevox™ (Crataeva nurvala L; Capparidaceae; Varuna) stem bark extract standardised for 1.5% lupeol: non-standardised Equisetum arvense L. (Equisetaceae; Horsetail) stem extract; and, non-standardised Lindera aggregata Sims. The primary outcome for this study is the frequency of nocturia. Secondary outcomes include safety, quality of life, and daytime incontinence. Each participation will be involved in the trial for 32 weeks including contact with the research team every 2 weeks for the first 8 weeks and then every 8 weeks until trial completion. DISCUSSION: This study examines a novel treatment for an under-researched health condition affecting many children. Despite the availability of several therapies for NE, there is insufficient evidence to support the use of any one intervention and as such this randomised placebo-controlled phase II trial will be an important contribution to understanding potential new treatments for this condition. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registration Number: 12618000288224. PROTOCOL: 23 February 2018, version 1.1. DOI: 10.1186/s12887-019-1797-8 PMCID: PMC6842251 PMID: 31706286 [Indexed for MEDLINE] Conflict of interest statement: This research team received funding from Siepel Group Pty Ltd. for this trial. This funding source had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results.

Urox containing concentrated extracts of Crataeva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root, in the treatment of symptoms of overactive bladder and urinary incontinence: a phase 2, randomised, double-blind placebo controlled trial.

6. BMC Complement Altern Med. 2018 Jan 31;18(1):42. doi: 10.1186/s12906-018-2101-4. Urox containing concentrated extracts of Crataeva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root, in the treatment of symptoms of overactive bladder and urinary incontinence: a phase 2, randomised, double-blind placebo controlled trial. Schoendorfer N(1), Sharp N(1), Seipel T(2)(3), Schauss AG(4), Ahuja KDK(5). Author information: (1)School of Medicine, University of Queensland, Herston, Australia. (2)Occidental Medicine Department, Endeavour College of Natural Health, Brisbane, Queensland, Australia. (3)Seipel Group, Brisbane, Australia. (4)Bio5 Institute, Office of Research, Discovery and Innovation, and College of Science, University of Arizona; and, AIBMR Life Sciences, Seattle, Washington, USA. (5)School of Health Sciences, University of Tasmania, Locked Bag 1322, Launceston, Tasmania, 7250, Australia. Kiran.Ahuja@utas.edu.au. BACKGROUND: Storage lower urinary tract symptoms (LUTS) including overactive bladder (OAB) and urinary incontinence (UI) affect millions of people worldwide, significantly impacting quality of life. Plant based medicines have been documented both empirically and in emerging scientific research to have varying benefits in reducing bladder symptoms. We assessed the efficacy of Urox®, a proprietary combination of phytomedicine extracts including, Cratevox™ (Crataeva nurvala) stem bark, Equisetem arvense stem and Lindera aggregata root, in reducing symptoms of OAB and UI. METHODS: Efficacy of the herbal combination on a variety of bladder symptoms compared to an identical placebo, were documented in a randomised, double-blind, placebo controlled trial conducted at two primary care centres. Data were collected at baseline, 2, 4 and 8 weeks, with the primary outcome being self-reported urinary frequency. Statistical analysis included mixed effects ordered logistic regression with post hoc Holm's test to account for repeated measures, and included an intention-to-treat analysis. RESULTS: One hundred and fifty participants (59% female, aged; mean ± SD; 63.5 ± 13.1 years) took part in the study. At week 8, urinary day frequency was significantly lower (OR 0.01; 95%CI 0.01 to 0.02; p < 0.001) in response to treatment (mean ± SD; 7.69 ± 2.15/day) compared to placebo (10.95 ± 2.47/day). Similarly, episodes of nocturia were significantly fewer (OR 0.03; 95%CI 0.02 to 0.05) after 8 weeks of treatment (2.16 ± 1.49/night) versus placebo (3.14 ± 1.36/night). Symptoms of urgency (OR 0.02; 95%CI 0.01 to 0.03), and total incontinence (OR 0.03; 95% CI 0.01 to 0.06) were also lower (all p < 0.01) in the treatment group. Significant improvements in quality of life were reported after treatment in comparison to placebo. No significant side effects were observed resulting in withdrawal from treatment. CONCLUSIONS: The outcome of this study demonstrated both statistical significance and clinical relevance in reducing symptoms of OAB, urinary frequency and/or urgency and incontinence. The demonstrated viability of the herbal combination to serve as an effective treatment, with minimal side-effects, warrants further longer term research and consideration by clinicians. TRIAL REGISTRATION: NCT02396160 (registered on 17 March 2015 - before any statistical analyses commenced). DOI: 10.1186/s12906-018-2101-4 PMCID: PMC5793427 PMID: 29385990 [Indexed for MEDLINE] Conflict of interest statement: ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The study was approved by the Ethics Committee of Endeavour College of Natural Health (Queensland, Australia). All participants provided written informed consent. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: All authors have completed the ICMJE uniform disclosure at www.icmje.org/coi_disclosure.pdf and declare: TS is the inventor of the US patent, Herbal Compositions For The Prevention Or Treatment Of Urinary Incontinence And Overactive Bladder, U.S. Patent Number No. 9,452,191, for the formulation assessed in the trial. Seipel Group provided funding and materials for this study, and employs TS. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Horsetail mixture on rheumatoid arthritis and its regulation on TNF-α and IL-10.

7. Pak J Pharm Sci. 2014 Nov;27(6 Suppl):2019-23. Horsetail mixture on rheumatoid arthritis and its regulation on TNF-α and IL-10. Jiang X(1), Qu Q(2), Li M(2), Miao S(2), Li X(2), Cai W(2). Author information: (1)Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China / Department of Kidney Transplantation, People's Hospital of Zhengzhou, Zhengzhou, China. (2)Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Taking autoimmune inflammation of rheumatoid arthritis as entry point, this paper discussed the clinical effect of horsetail mixture on rheumatoid arthritis (RA) and its mechanism. A total of 60 cases of patients with RA were randomly divided into experimental group and control group using randomized controlled trial. We observed its biochemistry, TNF-α and IL-10 before and after treatment, and then systematically assessed the clinical effect of horsetail on RA. Results showed that the total effective rate of experimental group was 80%, while that of control group was 16.67%. After statistical treatment, the differences between two groups were significant (p<0.01). Comparison of the difference value of TNF-α (p<0.05) and IL-0.05 in serum between groups before and after treatment, there were significant differences. Comparison of CRP within group before and after treatment was significantly different (p<0.05), while comparison of CRP between groups was not significantly different (p>0.05). Comparison of ESR and RF within group before and after treatment was significantly different (p<0.01), and comparison of them between groups was also significantly different (p<0.05). Comparison of difference values within group before and after treatment were also significantly different (p<0.01). It was concluded that horsetail mixture has remarkable curative effect on rheumatoid arthritis, and its clinical application is safe and reliable. It has obvious down regulatory effect on cell factor TNF-α related to RA, that is, it can down regulate the level of pre-inflammatory factor TNF-α as well as the level of anti-inflammatory factor IL-10. Therefore, it is considered that the regulating effect of horsetail mixture on TNF-α and IL-10 is one of the mechanisms of its treatment on RA. PMID: 25410066 [Indexed for MEDLINE]

Randomized controlled trial of a water-soluble nail lacquer based on hydroxypropyl-chitosan (HPCH), in the management of nail psoriasis.

8. Clin Cosmet Investig Dermatol. 2014 May 27;7:185-90. doi: 10.2147/CCID.S61659. eCollection 2014. Randomized controlled trial of a water-soluble nail lacquer based on hydroxypropyl-chitosan (HPCH), in the management of nail psoriasis. Cantoresi F(1), Caserini M(2), Bidoli A(1), Maggio F(1), Marino R(1), Carnevale C(1), Sorgi P(1), Palmieri R(2). Author information: (1)Department of Dermatology, Sapienza University, Rome, Italy. (2)Scientific Department, Polichem SA, Lugano, Switzerland. BACKGROUND: Nail psoriasis occurs in up to 50% of patients affected by psoriasis, with a significant impact on quality of life that leads to a real clinical need for new therapeutic options. AIM: To confirm whether the strengthening and hardening properties of the hydroxypropyl-chitosan (HPCH) nail lacquer could improve the structure of the nail plates on psoriatic nails. MATERIALS AND METHODS: A randomized, double-blind, placebo controlled, parallel-group trial was carried out to evaluate the efficacy and tolerability of a hydrosoluble nail lacquer containing HPCH, Equisetum arvense, and methylsulfonylmethane on nail psoriasis. The test product or a placebo was applied once daily for 24 weeks to all fingernails. Efficacy assessments were performed on the target fingernail by means of the modified Nail Psoriasis Severity Index score. A cut-off score of 4 was considered to define the clinical cure rate (ie, Cure ≤4, Failure >4). RESULTS: After 24 weeks, the clinical cure rate showed the statistically significant superiority of the HPCH nail lacquer compared to placebo in both the intention-to-treat (Fisher's exact test, P=0.0445) and the per protocol population (Fisher's exact test, P=0.0437). This superiority was already present after 16 weeks of treatment. Moreover, the analysis of the modified Nail Psoriasis Severity Index-50 showed a statistically significant clinical improvement after 12 weeks of treatment in comparison to the results obtained after 8 weeks (Fisher's exact test, P<0.05). CONCLUSION: The trial showed that HPCH nail lacquer could be a new, valid, effective, and safe option for decreasing the signs of nail dystrophy in psoriatic patients. DOI: 10.2147/CCID.S61659 PMCID: PMC4041289 PMID: 24904219

[Assessment of clinical usefulness of Eviprostat for benign prostatic hyperplasia--comparison of Eviprostat tablet with a formulation containing two-times more active ingredients].

9. Hinyokika Kiyo. 2008 Jun;54(6):435-45. [Assessment of clinical usefulness of Eviprostat for benign prostatic hyperplasia--comparison of Eviprostat tablet with a formulation containing two-times more active ingredients]. [Article in Japanese] Tamaki M(1), Nakashima M, Nishiyama R, Ikeda H, Hiura M, Kanaoka T, Nakano T, Hayashi T, Ogawa O. Author information: (1)Department of Urology, Japanese Red Cross Society Wakayama Medical Center. We compared the usefulness of Eviprostat tablet, a therapeutic agent for benign prostatic hyperplasia (BPH), and EVI-F tablet, a new formulation of Eviprostat containing two times more active ingredients (Chimaphila umbellata extract, Populus tremula extract, Pulsatilla pratensis extract, Equisetum arvense extract and purified wheat germ oil) and consequently designed to reduce the number of tablets per dose by half. In this study, patients with BPH were randomly assigned to either Eviprostat group (6 tabs/day) or EVI-F group (3 tabs/day) using the envelope method. The clinical efficacy of these two drugs were evaluated by the International Prostate Symptom Score (IPSS) and QOL score at the end of the treatment period, and their safety was evaluated by the incidence of side effects. Based on the clinical study guidelines for dysuria, the change in the IPSS total score and QOL score were comparable to the previously reported data for other treatment agents for BPH, and these indices showed gradual improvement with the treatment period. Both treatments were well tolerated. The clinical usefulness of the monotherapy with EVI-F tablet or Eviprostat tablet was reasonably demonstrated in this study. Furthermore, both treatments reduced nocturia, which has an impact on the QOL of patients with BPH. PMID: 18634442 [Indexed for MEDLINE]